Biomea Fusion, Inc. (BMEA) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Redwood City, CA, United States. El CEO actual es Michael J. Hitchcock.
BMEA tiene fecha de IPO 2021-04-16, 79 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $116.02M.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
